HMPL 011

Drug Profile

HMPL 011

Alternative Names: HMPL-011

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Hutchison MediPharma
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Interleukin 10 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Autoimmune disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Australia (PO)
  • 11 Nov 2010 Pharmacodynamics data from a preclinical trial in Rheumatoid arthritis presented at the 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2010)
  • 28 Oct 2009 Phase-I clinical trials in healthy volunteers in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top